Compugen (CGEN)

259
+5(+1.85%)
  • वॉल्यूम:
    6,972
  • बिड/आस्क:
    259/260
  • दिन की रेंज:
    254 - 260

CGEN समीक्षा

पिछला बंद
254
दिन की रेंज
254-260
आय
7.5M
खुला
254
52 सप्ताह रेंज
217-1,106
ईपीएस
-0.389
वॉल्यूम
6,972
मार्केट कैप
224.36M
लाभांश (यील्ड)
N/A
(N/A)
औसत वॉल्यूम (3एम)
203,004
पी/ई अनुपात
-1.82
बीटा
2.7
1- वर्ष बदलाव
-75.99%
बकाया शेयर
86,624,643
अगली कमाई तिथि
09 मई 2023
Compugen पर आपकी भावना क्या है?
या
समुदाय परिणामों को देखने के लिए वोट करें!

Compugen कंपनी प्रोफाइल

Compugen कंपनी प्रोफाइल

  • प्रकार:इक्विटी
  • बाज़ार:इजराइल
  • आईसआईन:IL0010852080
  • एस/न:1085208

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

और पढ़ें

तकनीकी सारांश

प्रकार
5 मिनट
15 मिनट
प्रति घंटा
दैनिक
मासिक
मूविंग एवरेजखरीदेंखरीदेंतटस्थमजबूत विक्रयमजबूत विक्रय
तकनीकी संकेतकमजबूत खरीदखरीदेंतटस्थमजबूत विक्रयमजबूत विक्रय
सारांशमजबूत खरीदखरीदेंतटस्थमजबूत विक्रयमजबूत विक्रय